Home Newsfeeds Cowen & Co. Downgrades Tricida to Market Perform

Cowen & Co. Downgrades Tricida to Market Perform

Cowen & Co. analyst Phil Nadeau downgrades Tricida (NASDAQ:TCDA) from Outperform to Market Perform.

byBenzinga Newsdesk

October 24, 2022

1 minute read

Cowen & Co. analyst Phil Nadeau downgrades Tricida (NASDAQ:TCDA) from Outperform to Market Perform.

This Tesla Analyst Must Be On ‘Hallucinogenic Drugs,’ Says Value Investor In Response To Morgan Stanley’s Value Proposition

By Adam Eckert

November 23, 5:56 PM

As Tesla Inc (NASDAQ: TSLA) shares continued to slip toward Morgan Stanley's bear case, analyst Adam Jonas started to wonder if Tesla was leaning into value territory.

Citigroup Maintains Buy on APi Gr, Raises Price Target to $24

By Benzinga Newsdesk

December 9, 1:36 PM

Citigroup analyst Andrew Kaplowitz maintains APi Gr (NYSE:APG) with a Buy and raises the price target from $21 to $24.

APG

UBS Maintains Neutral on Hyliion Holdings, Lowers Price Target to $3.25

By Benzinga Newsdesk

March 2, 10:42 AM

UBS analyst Dennis Geiger maintains Hyliion Holdings (NYSE:HYLN) with a Neutral and lowers the price target from $3.5 to $3.25.

HYLN

Armata Pharmaceuticals Announces Clearance Of IND For Prosthetic Joint Infections

By Benzinga Newsdesk

August 1, 8:04 AM

Second indication for AP-SA02 which targets Staphylococcus aureus including MRSA Potential to significantly improve PJI patient outcomes Expands Armata's pursuit of phage therapy as a solution for

ARMP

Cowen & Co. Downgrades Tricida to Market Perform

Related Posts

This Tesla Analyst Must Be On ‘Hallucinogenic Drugs,’ Says Value Investor In Response To Morgan Stanley’s Value Proposition

Citigroup Maintains Buy on APi Gr, Raises Price Target to $24

UBS Maintains Neutral on Hyliion Holdings, Lowers Price Target to $3.25

Armata Pharmaceuticals Announces Clearance Of IND For Prosthetic Joint Infections